Aberrant EZH2 expression and activity have also been linked to tumorigenesis; EZH2 was found to be overexpressed in breast, prostate, and renal cancers, where its levels correlate with poor prognosis (Varambally et al., 2002; Kleer et al., 2003; Wagener et al., 2008). This evidence concerns the gene EZH2 and renal carcinoma.